Table 1.
Patient data
| Patient | Sex | Drugs at Surgery | Duration of Epilepsy, yr | Age at Surgery, yr |
|---|---|---|---|---|
| MTLE | ||||
| 1 | M | Carbemazepine, Vigabatrin | 7 | 30 |
| 2 | M | Carbemazepine | 31 | 41 |
| 3 | M | VPA, Carbemazepine, Mysoline, Gabapentin | 33 | 37 |
| 4 | F | Carbemazepine | 20 | 29 |
| 5 | F | Carbemazepine | 22 | 29 |
| 6 | F | Carbemazepine | 6 | 36 |
| 7 | F | Carbemazepine, Gabapentin, Mysoline | 27 | 45 |
| 8 | Phenytoin, Gabapentin | 10 | 12 | |
| Mean | 19.5 ± 4.3 | 32.4 ± 4.1 | ||
| MaTLE | ||||
| 9 | F | Carbemazepine VPA, | 3 | 29 |
| 10 | F | Carbemazepine, Lamotrigine | 19 | 35 |
| 11 | F | Phenytoin, VPA | 5 | 6 |
| 12 | M | Carbemazepine | 2 | 62 |
| Mean | 7.2 ± 4.6 | 33 ± 13.3 | ||
| PTLE | ||||
| 13 | M | Phenytoin | 15 | 29 |
| 14 | F | Carbemazepine, Lamotrigine | 41 | 45 |
| 15 | F | Carbemazepine, Topirimate | 6 | 34 |
| Mean | 20.7 ± 12.9 | 36.0 ± 5.8 |
-
The duration of epilepsy was measured from the time of the first unprovoked seizure. Most of these patients were on multiple anticonvulsants at the time of surgery. There was extensive variability within this population in the ages at surgery and the duration of their epilepsy. Values are means ± SE. MTLE, mesial temporal sclerosis; MaTLE, mass-associated temporal lobe epilepsy; PTLE, paradoxical type of temporal lobe epilepsy.